magnolol has been researched along with Infarction, Middle Cerebral Artery in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Liu, X; Liu, Y; Wang, Y; Zhu, Y | 1 |
| Chen, HY; Chen, TY; Hung, YC; Lee, EJ; Lee, WT; Lin, MH; Tai, SH; Wu, TS | 1 |
2 other study(ies) available for magnolol and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Magnolol derivative 002C-3 protects brain against ischemia-reperfusion injury via inhibiting apoptosis and autophagy.
Topics: Animals; Apoptosis; Autophagy; Biphenyl Compounds; Brain; Brain Infarction; Caspase 3; Infarction, Middle Cerebral Artery; Lignans; Male; Mice; Neuroprotective Agents; Rats, Sprague-Dawley; Reperfusion Injury | 2015 |
Magnolol reduces glutamate-induced neuronal excitotoxicity and protects against permanent focal cerebral ischemia up to 4 hours.
Topics: Animals; Biphenyl Compounds; Brain; Calcium; Cells, Cultured; Cerebral Infarction; Dose-Response Relationship, Drug; Glutamic Acid; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Lignans; Male; Neurons; Neuroprotective Agents; Neuropsychological Tests; Rats; Rats, Sprague-Dawley; Time Factors | 2012 |